Last reviewed · How we verify

Naloxone + Ketamine — Competitive Intelligence Brief

Naloxone + Ketamine (Naloxone + Ketamine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist + NMDA receptor antagonist combination. Area: Emergency Medicine / Anesthesia.

marketed Opioid antagonist + NMDA receptor antagonist combination Opioid receptors (mu, delta, kappa) and NMDA receptor Emergency Medicine / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Naloxone + Ketamine (Naloxone + Ketamine) — Ullevaal University Hospital. Naloxone blocks opioid receptors to reverse opioid overdose, while ketamine provides dissociative anesthesia and analgesia through NMDA receptor antagonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Naloxone + Ketamine TARGET Naloxone + Ketamine Ullevaal University Hospital marketed Opioid antagonist + NMDA receptor antagonist combination Opioid receptors (mu, delta, kappa) and NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist + NMDA receptor antagonist combination class)

  1. Ullevaal University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naloxone + Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/naloxone-ketamine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: